Puma Biotechnology, Inc.
Puma Biotechnology, Inc. (PBYI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
pbyi · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Puma Biotechnology, Inc. (PBYI) measures how much investors pay for each dollar of the company's trailing earnings. PBYI's current PE ratio of 14.28x is calculated by dividing its stock price of $6.85 by its TTM earnings per share of $0.48. +79.2% elevated vs 5Y avg 8.0x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%9.5x
MedianQ3 · 75%9.6x
Max
At 14.28x, PBYI's current P/E is higher than in 100% of its annual fiscal year readings over the past 3 years — historically elevated.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Puma Biotechnology, Inc.You PBYI | $349M | 14.28x | — | $0.48 |
 Abeona Therapeutics Inc. ABEO | $307M | 3.92x | — | $1.34 |
 Allogene Therapeutics, Inc. ALLO | $451M | N/A | — | -$0.87 |
 Arcturus Therapeutics Holdings Inc. ARCT | $202M | N/A | — | -$2.40 |
 Atea Pharmaceuticals, Inc. AVIR | $346M | N/A | — | -$1.94 |
 Eledon Pharmaceuticals, Inc. ELDN | $215M | N/A | — | -$0.56 |
 Humacyte, Inc. HUMA | $232M | N/A | — | -$0.26 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 9.56x | $0.62 | +95.2% | |
2024-12-31 FY2024 | 4.90x | $0.62 | -48.2% | |
2023-12-31 FY2023 | 9.45x | $0.46 | -100.0% | |
2022-12-31 FY2022 | — | $0.00 | — | |
2021-12-31 FY2021 | — | $-0.72 | — | |
2020-12-31 FY2020 | — | $-1.52 | — | |
2019-12-31 FY2019 | — | $-1.95 | — | |
2018-12-31 FY2018 | — | $-2.99 | — | |
2017-12-31 FY2017 | — | $-7.86 | — | |
2016-12-31 FY2016 | — | $-8.29 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Puma Biotechnology, Inc. (PBYI) measures how much investors pay for each dollar of the company's trailing earnings. PBYI's current PE ratio of 14.28x is calculated by dividing its stock price of $6.85 by its TTM earnings per share of $0.48.
Frequently asked questions
PBYI pe ratio · 6 questionsPBYI's current PE ratio is 14.28x as of 2026-06-09, based on a stock price of $6.85 and TTM EPS of $0.48. Data sourced from Financial Modeling Prep via PBYI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Puma Biotechnology, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09